Dear Editor,

We are pleased to answer the questions of the reviewers' and the manuscript (Manuscript NO.: 71879) has also extensively revised according to the reviewers' comments. The revisions in the manuscript have been marked in red. Some explanations regarding the revisions of our manuscript are as follows.

Answers to reviewers:

Reviewer#1:

1. Some phrases as "The latest clinical research on AI, ulcerative colitis, severe acute pancreatitis, and other benign diseases is summarized in Table 2." in section 4 needs rewritten. In this phrase AI seems part of the diseases mentioned.

Answer: "The latest clinical research on AI, ulcerative colitis, severe acute pancreatitis, and other benign diseases is summarized in Table 2." in section 4 has been rewritten as "The latest application of AI in ulcerative colitis, severe acute pancreatitis, gastric ulcer, gastritis and intestinal polyp is summarized in Table2."

2. Citations are where reference is given "Yao H et al established a fully automatic endoscopic disease grading video analysis system through AI." and "Namikawa K et al developed an advanced CNN (A-CNN) based on the original convolutional neural network and evaluated its applicability in the classification of gastric ulcers."

Answer: We have added reference [33] to"Yao H et al established a fully automatic endoscopic disease grading video analysis system through AI." and reference [45] to "Namikawa K et al developed an advanced CNN (A-CNN) based on the original convolutional neural network and evaluated its applicability in the classification of gastric ulcers." In the revised manuscript, we marked the reference [33] and [45] in red.

## Special instructions:

1. In the Supportive foundations, the grant numbers of the two supportive foundations were wrong. We have corrected the grant numbers and provided the approval documents (resubmitted online).

2. We have received the E-mail entitles "Notification on Copyright
License Agreement - World Journal of Gastroenterology Manuscript NO: 71879."

But one author named *Xu caiming* (xucaiming\_science@hotmail.com) did not receive the E-mail. So he could not accept and sign the Copyright License Agreement (CLA).

How about we change Xu caiming 's Email address to

*xucaiming002@163.com.* We will greatly appreciate it if you could spend some of your time sending the E-mail to *Xu caiming* (xucaiming002@163.com) again.

Best wishes.

Sincerely yours,

Guixin Zhang.